GTx falls on clinical hold for prostate cancer product

GTx Inc. (NASDAQ:GTXI) fell $2.11 (36%) to $3.69 on Tuesday after FDA placed a clinical hold on Capesaris ( GTx-758) following reports of an increased risk of venous thromboembolic events (VTE) in pat...